Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
1.
Skin Health Dis ; 2(3): e132, 2022 Sep.
Article in English | MEDLINE | ID: mdl-36092259

ABSTRACT

Background: The diagnosis of Scleroderma En Coup de Sabre (ECDS)/Parry Romberg Syndrome (PRS) is mainly based on characteristic clinical findings. Methods to objectively monitor the course of the disease in a standardized way are lacking. Objectives: This descriptive, retrospective, single centre cohort study aims to describe the contribution of 3D photographs in the assessment of the degree of facial asymmetry changes over time in growing children and adolescents with ECDS and PRS. Methods: Six patients diagnosed with ECDS/PRS, with a follow-up period of at least 24 months and at least three 3D photographs were included. Mirroring these 3D photographs was automatically performed using surface-based matching to generate a colour-coded distance map, illustrating the inter-surface distance and thereby asymmetry between the original and mirrored 3D photographs. The percentage of absolute distances between the original and mirrored 3D photograph were calculated. Results: In two patients, impressive decreases in the percentages of absolute distance levels over time were found, whereas the other patients did not show progression of asymmetry over time. Conclusion: This study shows the potential of 3D stereophotogrammetry as an objective tool to measure disease activity over time in patients with ECDS/PRS.

2.
Arthritis Rheumatol ; 73(7): 1220-1232, 2021 07.
Article in English | MEDLINE | ID: mdl-33452865

ABSTRACT

OBJECTIVE: To compare immune cell phenotype and function in psoriatic arthritis (PsA) versus psoriasis in order to better understand the pathogenesis of PsA. METHODS: In-depth immunophenotyping of different T cell and dendritic cell subsets was performed in patients with PsA, psoriasis, or axial spondyloarthritis and healthy controls. Subsequently, we analyzed cells from peripheral blood, synovial fluid (SF), and skin biopsy specimens using flow cytometry, along with high-throughput transcriptome analyses and functional assays on the specific cell populations that appeared to differentiate PsA from psoriasis. RESULTS: Compared to healthy controls, the peripheral blood of patients with PsA was characterized by an increase in regulatory CD4+ T cells and interleukin-17A (IL-17A) and IL-22 coproducing CD8+ T cells. One population specifically differentiated PsA from psoriasis: i.e., CD8+CCR10+ T cells were enriched in PsA. CD8+CCR10+ T cells expressed high levels of DNAX accessory molecule 1 and were effector memory cells that coexpressed skin-homing receptors CCR4 and cutaneous lymphocyte antigen. CD8+CCR10+ T cells were detected under inflammatory and homeostatic conditions in skin, but were not enriched in SF. Gene profiling further revealed that CD8+CCR10+ T cells expressed GATA3, FOXP3, and core transcriptional signature of tissue-resident memory T cells, including CD103. Specific genes, including RORC, IFNAR1, and ERAP1, were up-regulated in PsA compared to psoriasis. CD8+CCR10+ T cells were endowed with a Tc2/22-like cytokine profile, lacked cytotoxic potential, and displayed overall regulatory function. CONCLUSION: Tissue-resident memory CD8+ T cells derived from the skin are enhanced in the circulation of patients with PsA compared to patients with psoriasis alone. This may indicate that aberrances in cutaneous tissue homeostasis contribute to arthritis development.


Subject(s)
Arthritis, Psoriatic/immunology , CD8-Positive T-Lymphocytes/immunology , Psoriasis/immunology , Skin/immunology , T-Lymphocyte Subsets/immunology , T-Lymphocytes, Regulatory/immunology , Adult , Aminopeptidases/genetics , Antigens, CD/genetics , Antigens, Differentiation, T-Lymphocyte/immunology , Arthritis, Psoriatic/genetics , Arthritis, Psoriatic/pathology , CD8-Positive T-Lymphocytes/metabolism , Case-Control Studies , Female , Forkhead Transcription Factors/genetics , GATA3 Transcription Factor/genetics , Gene Expression Profiling , High-Throughput Nucleotide Sequencing , Humans , Immunologic Memory/immunology , Immunophenotyping , Integrin alpha Chains/genetics , Interleukin-17/immunology , Interleukins/immunology , Male , Middle Aged , Minor Histocompatibility Antigens/genetics , Nuclear Receptor Subfamily 1, Group F, Member 3/genetics , Oligosaccharides/metabolism , Psoriasis/genetics , Psoriasis/pathology , Receptor, Interferon alpha-beta/genetics , Receptors, CCR10/metabolism , Receptors, CCR4/metabolism , Sialyl Lewis X Antigen/analogs & derivatives , Sialyl Lewis X Antigen/metabolism , Skin/pathology , Spondylarthropathies/genetics , Spondylarthropathies/immunology , Spondylarthropathies/pathology , Synovial Fluid/cytology , T-Lymphocyte Subsets/metabolism , T-Lymphocytes, Cytotoxic/immunology , T-Lymphocytes, Regulatory/metabolism , Interleukin-22
3.
Rheumatology (Oxford) ; 60(2): 785-801, 2021 02 01.
Article in English | MEDLINE | ID: mdl-32810267

ABSTRACT

OBJECTIVES: Vasculopathy is an important hallmark of systemic chronic inflammatory connective tissue diseases (CICTD) and is associated with increased cardiovascular risk. We investigated disease-specific biomarker profiles associated with endothelial dysfunction, angiogenic homeostasis and (tissue) inflammation, and their relation to disease activity in rare CICTD. METHODS: A total of 38 serum proteins associated with endothelial (dys)function and inflammation were measured by multiplex-immunoassay in treatment-naive patients with localized scleroderma (LoS, 30), eosinophilic fasciitis (EF, 8) or (juvenile) dermatomyositis (34), 119 (follow-up) samples during treatment, and 65 controls. Data were analysed by unsupervised clustering, Spearman correlations, non-parametric t test and ANOVA. RESULTS: The systemic CICTD, EF and dermatomyositis, had distinct biomarker profiles, with 'signature' markers galectin-9 (dermatomyositis) and CCL4, CCL18, CXCL9, fetuin, fibronectin, galectin-1 and TSP-1 (EF). In LoS, CCL18, CXCL9 and CXCL10 were subtly increased. Furthermore, dermatomyositis and EF shared upregulation of markers related to interferon (CCL2, CXCL10), endothelial activation (VCAM-1), inhibition of angiogenesis (angiopoietin-2, sVEGFR-1) and inflammation/leucocyte chemo-attraction (CCL19, CXCL13, IL-18, YKL-40), as well as disturbance of the Angiopoietin-Tie receptor system and VEGF-VEGFR system. These profiles were related to disease activity, and largely normalized during treatment. However, a subgroup of CICTD patients showed continued elevation of CXCL10, CXCL13, galectin-9, IL-18, TNFR2, VCAM-1, and/or YKL-40 during clinically inactive disease, possibly indicating subclinical interferon-driven inflammation and/or endothelial dysfunction. CONCLUSION: CICTD-specific biomarker profiles revealed an anti-angiogenic, interferon-driven environment during active disease, with incomplete normalization under treatment. This warrants further investigation into monitoring of vascular biomarkers during clinical follow-up, or targeted interventions to minimize cardiovascular risk in the long term.


Subject(s)
Biomarkers/blood , Dermatomyositis , Endothelium, Vascular/immunology , Eosinophilia , Fasciitis , Scleroderma, Localized , Autoimmunity , Chemokine CXCL10/blood , Chemokine CXCL13/blood , Dermatomyositis/blood , Dermatomyositis/diagnosis , Eosinophilia/blood , Eosinophilia/diagnosis , Fasciitis/blood , Fasciitis/diagnosis , Female , Galectins/blood , Heart Disease Risk Factors , Humans , Male , Middle Aged , Monitoring, Immunologic/methods , Netherlands , Patient Acuity , Receptors, Tumor Necrosis Factor, Type II/blood , Scleroderma, Localized/blood , Scleroderma, Localized/diagnosis , Vascular Cell Adhesion Molecule-1/blood
4.
Eur J Immunol ; 50(1): 119-129, 2020 01.
Article in English | MEDLINE | ID: mdl-31424086

ABSTRACT

Systemic sclerosis (SSc), systemic lupus erythematosus (SLE) and primary Sjögrens syndrome (pSS) are clinically distinct systemic autoimmune diseases (SADs) that share molecular pathways. We quantified the frequency of circulating immune-cells in 169 patients with these SADs and 44 healty controls (HC) using mass-cytometry and assessed the diagnostic value of these results. Alterations in the frequency of immune-cell subsets were present in all SADs compared to HC. Most alterations, including a decrease of CD56hi NK-cells in SSc and IgM+ Bcells in pSS, were disease specific; only a reduced frequency of plasmacytoid dendritic cells was common between all SADs Strikingly, hierarchical clustering of SSc patients identified 4 clusters associated with different clinical phenotypes, and 9 of the 12 cell subset-alterations in SSc were also present during the preclinical-phase of the disease. Additionally, we found a strong association between the use of prednisone and alterations in B-cell subsets. Although differences in immune-cell frequencies between these SADs are apparent, the discriminative value thereof is too low for diagnostic purposes. Within each disease, mass cytometry analyses revealed distinct patterns between endophenotypes. Given the lack of tools enabling early diagnosis of SSc, our results justify further research into the value of cellular phenotyping as a diagnostic aid.


Subject(s)
Flow Cytometry/methods , Lupus Erythematosus, Systemic/immunology , Scleroderma, Systemic/immunology , Sjogren's Syndrome/immunology , Adult , Aged , Female , Humans , Lupus Erythematosus, Systemic/diagnosis , Male , Middle Aged , Phenotype , Scleroderma, Systemic/diagnosis , Sjogren's Syndrome/diagnosis
6.
Eur J Immunol ; 50(4): 548-557, 2020 04.
Article in English | MEDLINE | ID: mdl-31841217

ABSTRACT

Non-Hodgkin orbital lymphoma (NHOL) and idiopathic orbital inflammation (IOI) are common orbital conditions with largely unknown pathophysiology. To investigate the immune cell composition of these diseases, we performed standardized 29 parameter flow cytometry phenotyping in peripheral blood mononuclear cells of 18 NHOL patients, 21 IOI patients, and 41 unaffected controls. Automatic gating by FlowSOM revealed decreased abundance of meta-clusters containing dendritic cells in patients, which we confirmed by manual gating. A decreased percentage of (HLA-DR+ CD303+ CD123+ ) plasmacytoid dendritic cells (pDC) in the circulation of IOI patients and decreased (HLA-DR+ CD11c+ CD1c+ ) conventional dendritic cells (cDC) type-2 for IOI patients were replicated in an independent cohort of patients and controls. Meta-analysis of both cohorts demonstrated that pDCs are also decreased in blood of NHOL patients and highlighted that the decrease in blood cDC type-2 was specific for IOI patients compared to NHOL or controls. Deconvolution-based estimation of immune cells in transcriptomic data of 48 orbital biopsies revealed a decrease in the abundance of pDC and cDC populations within the orbital microenvironment of IOI patients. Collectively, these data suggest a previously underappreciated role for dendritic cells in orbital disorders.


Subject(s)
Dendritic Cells/immunology , Inflammation/immunology , Lymphoma, Non-Hodgkin/immunology , Orbit/immunology , Orbital Neoplasms/immunology , Adult , Cell Differentiation , Cohort Studies , Cytokines/metabolism , Dendritic Cells/pathology , Female , HLA-DR Antigens/metabolism , Humans , Inflammation/pathology , Lymphoma, Non-Hodgkin/pathology , Male , Middle Aged , Orbit/pathology , Orbital Neoplasms/pathology , Th2 Cells/immunology
7.
Ann Rheum Dis ; 78(9): 1249-1259, 2019 09.
Article in English | MEDLINE | ID: mdl-31126957

ABSTRACT

OBJECTIVES: Systemic sclerosis (SSc) is an autoimmune disease with unknown pathogenesis manifested by inflammation, vasculopathy and fibrosis in skin and internal organs. Type I interferon signature found in SSc propelled us to study plasmacytoid dendritic cells (pDCs) in this disease. We aimed to identify candidate pathways underlying pDC aberrancies in SSc and to validate its function on pDC biology. METHODS: In total, 1193 patients with SSc were compared with 1387 healthy donors and 8 patients with localised scleroderma. PCR-based transcription factor profiling and methylation status analyses, single nucleotide polymorphism genotyping by sequencing and flow cytometry analysis were performed in pDCs isolated from the circulation of healthy controls or patients with SSc. pDCs were also cultured under hypoxia, inhibitors of methylation and hypoxia-inducible factors and runt-related transcription factor 3 (RUNX3) levels were determined. To study Runx3 function, Itgax-Cre:Runx3f/f mice were used in in vitro functional assay and bleomycin-induced SSc skin inflammation and fibrosis model. RESULTS: Here, we show downregulation of transcription factor RUNX3 in SSc pDCs. A higher methylation status of the RUNX3 gene, which is associated with polymorphism rs6672420, correlates with lower RUNX3 expression and SSc susceptibility. Hypoxia is another factor that decreases RUNX3 level in pDC. Mouse pDCs deficient of Runx3 show enhanced maturation markers on CpG stimulation. In vivo, deletion of Runx3 in dendritic cell leads to spontaneous induction of skin fibrosis in untreated mice and increased severity of bleomycin-induced skin fibrosis. CONCLUSIONS: We show at least two pathways potentially causing low RUNX3 level in SSc pDCs, and we demonstrate the detrimental effect of loss of Runx3 in SSc model further underscoring the role of pDCs in this disease.


Subject(s)
Core Binding Factor Alpha 3 Subunit/genetics , Dendritic Cells/metabolism , Gene Expression Regulation , RNA/genetics , Scleroderma, Systemic/genetics , Skin/pathology , Animals , Core Binding Factor Alpha 3 Subunit/biosynthesis , Dendritic Cells/pathology , Disease Models, Animal , Disease Progression , Fibroblasts/metabolism , Fibroblasts/pathology , Fibrosis/genetics , Fibrosis/metabolism , Fibrosis/pathology , Humans , Mice , Scleroderma, Systemic/metabolism , Scleroderma, Systemic/pathology , Skin/metabolism
8.
Arthritis Rheumatol ; 71(10): 1711-1722, 2019 10.
Article in English | MEDLINE | ID: mdl-31012544

ABSTRACT

OBJECTIVE: To analyze the potential role of semaphorin 4A (Sema4A) in inflammatory and fibrotic processes involved in the pathology of systemic sclerosis (SSc). METHODS: Sema4A levels in the plasma of healthy controls (n = 11) and SSc patients (n = 20) were determined by enzyme-linked immunosorbent assay (ELISA). The expression of Sema4A and its receptors in monocytes and CD4+ T cells from healthy controls and SSc patients (n = 6-7 per group) was determined by ELISA and flow cytometry. Th17 cytokine production by CD4+ T cells (n = 5-7) was analyzed by ELISA and flow cytometry. The production of inflammatory mediators and extracellular matrix (ECM) components by dermal fibroblast cells (n = 6) was analyzed by quantitative polymerase chain reaction, ELISA, Western blotting, confocal microscopy, and ECM deposition assay. RESULTS: Plasma levels of Sema4A, and Sema4A expression by circulating monocytes and CD4+ T cells, were significantly higher in SSc patients than in healthy controls (P < 0.05). Inflammatory mediators significantly up-regulated the secretion of Sema4A by monocytes and CD4+ T cells from SSc patients (P < 0.05 versus unstimulated SSc cells). Functional assays showed that Sema4A significantly enhanced the expression of Th17 cytokines induced by CD3/CD28 in total CD4+ T cells as well in different CD4+ T cell subsets (P < 0.05 versus unstimulated SSc cells). Finally, Sema4A induced a profibrotic phenotype in dermal fibroblasts from both healthy controls and SSc patients, which was abrogated by blocking or silencing the expression of Sema4A receptors. CONCLUSION: Our findings indicate that Sema4A plays direct and dual roles in promoting inflammation and fibrosis, 2 main features of SSc, suggesting that Sema4A might be a novel therapeutic target in SSc.


Subject(s)
CD4-Positive T-Lymphocytes/immunology , Cytokines/immunology , Fibroblasts/metabolism , Fibrosis/metabolism , Inflammation/metabolism , Monocytes/immunology , Scleroderma, Systemic/metabolism , Semaphorins/metabolism , Adult , Blotting, Western , Case-Control Studies , Enzyme-Linked Immunosorbent Assay , Extracellular Matrix/metabolism , Extracellular Matrix/pathology , Female , Fibroblasts/immunology , Fibroblasts/pathology , Fibrosis/pathology , Humans , Inflammation/immunology , Male , Microscopy, Confocal , Middle Aged , Polymerase Chain Reaction , Reverse Transcriptase Polymerase Chain Reaction , Scleroderma, Systemic/immunology , Scleroderma, Systemic/pathology , Skin/cytology , Th17 Cells/immunology
9.
Arthritis Rheumatol ; 71(8): 1377-1390, 2019 08.
Article in English | MEDLINE | ID: mdl-30861625

ABSTRACT

OBJECTIVE: Objective evaluation of disease activity is challenging in patients with juvenile dermatomyositis (DM) due to a lack of reliable biomarkers, but it is crucial to avoid both under- and overtreatment of patients. Recently, we identified 2 proteins, galectin-9 and CXCL10, whose levels are highly correlated with the extent of juvenile DM disease activity. This study was undertaken to validate galectin-9 and CXCL10 as biomarkers for disease activity in juvenile DM, and to assess their disease specificity and potency in predicting the occurrence of flares. METHODS: Levels of galectin-9 and CXCL10 were measured by multiplex immunoassay in serum samples from 125 unique patients with juvenile DM in 3 international cross-sectional cohorts and a local longitudinal cohort. The disease specificity of both proteins was examined in 50 adult patients with DM or nonspecific myositis (NSM) and 61 patients with other systemic autoimmune diseases. RESULTS: Both cross-sectionally and longitudinally, galectin-9 and CXCL10 outperformed the currently used laboratory marker, creatine kinase (CK), in distinguishing between juvenile DM patients with active disease and those in remission (area under the receiver operating characteristic curve [AUC] 0.86-0.90 for galectin-9 and CXCL10; AUC 0.66-0.68 for CK). The sensitivity and specificity for active disease in juvenile DM was 0.84 and 0.92, respectively, for galectin-9 and 0.87 and 1.00, respectively, for CXCL10. In 10 patients with juvenile DM who experienced a flare and were prospectively followed up, continuously elevated or rising biomarker levels suggested an imminent flare up to several months before the onset of symptoms, even in the absence of elevated CK levels. Galectin-9 and CXCL10 distinguished between active disease and remission in adult patients with DM or NSM (P = 0.0126 for galectin-9 and P < 0.0001 for CXCL10) and were suited for measurement in minimally invasive dried blood spots (healthy controls versus juvenile DM, P = 0.0040 for galectin-9 and P < 0.0001 for CXCL10). CONCLUSION: In this study, galectin-9 and CXCL10 were validated as sensitive and reliable biomarkers for disease activity in juvenile DM. Implementation of these biomarkers into clinical practice as tools to monitor disease activity and guide treatment might facilitate personalized treatment strategies.


Subject(s)
Chemokine CXCL10/blood , Dermatomyositis/blood , Dermatomyositis/diagnosis , Galectins/blood , Severity of Illness Index , Adolescent , Adult , Biomarkers/blood , Child , Creatine Kinase/blood , Cross-Sectional Studies , Female , Follow-Up Studies , Humans , Longitudinal Studies , Male , Predictive Value of Tests , Prospective Studies , Reproducibility of Results , Sensitivity and Specificity , Young Adult
10.
Acta Derm Venereol ; 99(4): 386-392, 2019 Apr 01.
Article in English | MEDLINE | ID: mdl-30543381

ABSTRACT

Methotrexate (MTX) and biologics are frequently used treatments for psoriasis. Exploring patients' beliefs about their treatment may help to elucidate patients' attitudes towards these therapies. A cross-sectional survey was conducted using the Beliefs about Medicines Questionnaire-Specific (BMQ-Specific) in patients treated with methotrexate or biologics. BMQ-Specific scores (Necessity and Concerns scales) were calculated and patients were classified as "accepting", "indifferent", "ambivalent" or "sceptical" towards their treat-ment. Biologics users scored higher on the Necessity scale than did methotrexate users. Both groups had lower Concerns scores than Necessity scores. A high Necessity scale was associated with a low Psoriasis Area and Severity Index score in both groups and long treatment duration in the methotrexate group. Although this study cannot make a direct comparison, it was observed that most patients on biologics could be classified as "accepting" (59%), and most patients on MTX could be classified as "indifferent" (47%). In conclusion, the BMQ-Specific is useful to identify patients with a sceptical, ambivalent or indifferent profile. These profiles may negatively influence patient's attitude towards their medication.


Subject(s)
Biological Products/therapeutic use , Health Knowledge, Attitudes, Practice , Immunosuppressive Agents/therapeutic use , Medication Adherence , Methotrexate/therapeutic use , Psoriasis/drug therapy , Adult , Aged , Biological Products/adverse effects , Cross-Sectional Studies , Female , Humans , Immunosuppressive Agents/adverse effects , Male , Methotrexate/adverse effects , Middle Aged , Psoriasis/diagnosis , Psoriasis/immunology , Psoriasis/psychology , Surveys and Questionnaires , Treatment Outcome
11.
Ann Rheum Dis ; 77(12): 1810-1814, 2018 12.
Article in English | MEDLINE | ID: mdl-30185417

ABSTRACT

OBJECTIVE: The interferon (IFN) signature is related to disease activity and vascular disease in systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) and represents a promising therapeutic target. Quantification of the IFN signature is currently performed by gene expression analysis, limiting its current applicability in clinical practice. Therefore, the objective of this study was to establish an easy to measure biomarker for the IFN signature. METHODS: Serum levels of galectin-9, CXCL-10 (IP-10) and tumour necrosis factor receptor type II (TNF-RII) were measured in patients with SLE, SLE+APS and primary APS (PAPS) and healthy controls (n=148) after an initial screening of serum analytes in a smaller cohort (n=43). Analytes were correlated to measures of disease activity and the IFN signature. The performance of galectin-9, CXCL-10 and TNF-RII as biomarkers to detect the IFN signature was assessed by receiver operating characteristic curves. RESULTS: Galectin-9, CXCL-10 and TNF-RII were elevated in patients with SLE, SLE+APS and PAPS (p<0.05) and correlated with disease activity and tissue factor expression. Galectin-9 correlated stronger than CXCL-10 or TNF-RII with the IFN score (r=0.70, p<0.001) and was superior to CXCL-10 or TNF-RII in detecting the IFN signature (area under the curve (AUC) 0.86). Importantly, in patients with SLE(±APS), galectin-9 was also superior to anti-dsDNA antibody (AUC 0.70), or complement C3 (AUC 0.70) and C4 (AUC 0.78) levels in detecting the IFN signature. CONCLUSION: Galectin-9 is a novel, easy to measure hence clinically applicable biomarker to detect the IFN signature in patients with systemic autoimmune diseases such as SLE and APS.


Subject(s)
Antiphospholipid Syndrome/blood , Biomarkers/blood , Galectins/blood , Interferons/analysis , Lupus Erythematosus, Systemic/blood , Adult , Antiphospholipid Syndrome/immunology , Female , Humans , Lupus Erythematosus, Systemic/immunology , Male , Middle Aged
12.
J Autoimmun ; 89: 162-170, 2018 05.
Article in English | MEDLINE | ID: mdl-29371048

ABSTRACT

OBJECTIVE: MicroRNAs (miRNAs) are regulatory molecules, which have been addressed as potential biomarkers and therapeutic targets in rheumatic diseases. Here, we investigated the miRNA signature in the serum of systemic sclerosis (SSc) patients and we further assessed their expression in early stages of the disease. METHODS: The levels of 758 miRNAs were evaluated in the serum of 26 SSc patients as compared to 9 healthy controls by using an Openarray platform. Three miRNAs were examined in an additional cohort of 107 SSc patients and 24 healthy donors by single qPCR. MiR-483-5p expression was further analysed in the serum of patients with localized scleroderma (LoS) (n = 22), systemic lupus erythematosus (SLE) (n = 33) and primary Sjögren's syndrome (pSS) (n = 23). The function of miR-483-5p was examined by transfecting miR-483-5p into primary human dermal fibroblasts and pulmonary endothelial cells. RESULTS: 30 miRNAs were significantly increased in patients with SSc. Of these, miR-483-5p showed reproducibly higher levels in an independent SSc cohort and was also elevated in patients with preclinical-SSc symptoms (early SSc). Notably, miR-483-5p was not differentially expressed in patients with SLE or pSS, whereas it was up-regulated in LoS, indicating that this miRNA could be involved in the development of skin fibrosis. Consistently, miR-483-5p overexpression in fibroblasts and endothelial cells modulated the expression of fibrosis-related genes. CONCLUSIONS: Our findings showed that miR-483-5p is up-regulated in the serum of SSc patients, from the early stages of the disease onwards, and indicated its potential function as a fine regulator of fibrosis in SSc.


Subject(s)
Endothelial Cells/physiology , Fibroblasts/physiology , MicroRNAs/genetics , Scleroderma, Systemic/genetics , Skin/pathology , Adult , Aged , Cohort Studies , Female , Fibrosis , Genetic Testing , Humans , Male , Middle Aged , Up-Regulation
13.
J Am Acad Dermatol ; 77(3): 512-517.e5, 2017 Sep.
Article in English | MEDLINE | ID: mdl-28734566

ABSTRACT

BACKGROUND: Eosinophilic fasciitis (EF) is a connective tissue disease with an unknown long-term course. OBJECTIVE: To evaluate presence and determinants of residual disease damage in patients with EF after long-term follow-up. METHODS: Patients with biopsy-proven EF were included for this cross-sectional study. Outcome measures included the Physician's Global Assessment of Disease Activity, Physician's Global Assessment of Damage (PhysGA-D), skin pliability scores, passive range of motion, and health-related quality of Life (HRQoL) questionnaires. RESULTS: In total, 35 patients (24 of whom were female [68.6%]) with a median age of 60 years participated. All patients had detectable residual damage. Impairment of HRQoL, assessed by the Dermatology Quality of Life Index and the 36-Item Short-Form Survey, correlated to the extent of residual damage. The PhysGA-D score at participation correlated to signs of severe disease at presentation, such as increased C-reactive protein level (Spearman's rho [rs ] = 0.486, P = .006), involvement of the neck (rs = 0.528, P = .001) and trunk (rs = 0.483, P = .003), prolonged time to disease remission (rs = 0.575, P = .003), and presence of concomitant morphea (rs = 0.349, P = .040). Lastly, maximum methotrexate dose correlated negatively to PhysGA-D score at study participation (rs = -0.393, P = .022). LIMITATIONS: Sample size. CONCLUSION: All patients with EF had detectable residual damage. Impairment of HRQoL correlated to the extent of residual damage. Advanced age and signs of severe disease at presentation were associated with the severity of residual damage.


Subject(s)
Eosinophilia/therapy , Fasciitis/therapy , Adult , Aged , Cross-Sectional Studies , Female , Humans , Male , Middle Aged , Time Factors , Treatment Outcome
14.
Am J Clin Dermatol ; 18(4): 491-512, 2017 Aug.
Article in English | MEDLINE | ID: mdl-28303481

ABSTRACT

Morphea, also known as localized scleroderma, encompasses a group of idiopathic sclerotic skin diseases. The spectrum ranges from relatively mild phenotypes, which generally cause few problems besides local discomfort and visible disfigurement, to subtypes with severe complications such as joint contractures and limb length discrepancies. Eosinophilic fasciitis (EF, Shulman syndrome) is often regarded as belonging to the severe end of the morphea spectrum. The exact driving mechanisms behind morphea and EF pathogenesis remain to be elucidated. However, extensive extracellular matrix formation and autoimmune dysfunction are thought to be key pathogenic processes. Likewise, these processes are considered essential in systemic sclerosis (SSc) pathogenesis. In addition, similarities in clinical presentation between morphea and SSc have led to many theories about their relatedness. Importantly, morphea may be differentiated from SSc based on absence of sclerodactyly, Raynaud's phenomenon, and nailfold capillary changes. The diagnosis of morphea is often based on characteristic clinical findings. Histopathological evaluation of skin biopsies and laboratory tests are not necessary in the majority of morphea cases. However, full-thickness skin biopsies, containing fascia and muscle tissue, are required for the diagnosis of EF. Monitoring of disease activity and damage, especially of subcutaneous involvement, is one of the most challenging aspects of morphea care. Therefore, data harmonization is crucial for optimizing standard care and for comparability of study results. Recently, the localized scleroderma cutaneous assessment tool (LoSCAT) has been developed and validated for morphea. The LoSCAT is currently the most widely reported outcome measure for morphea. Care providers should take disease subtype, degree of activity, depth of involvement, and quality-of-life impairments into account when initiating treatment. In most patients with circumscribed superficial subtypes, treatment with topical therapies suffices. In more widespread disease, UVA1 phototherapy or systemic treatment with methotrexate (MTX), with or without a systemic corticosteroid combination, should be initiated. Disappointingly, few alternatives for MTX have been described and additional research is still needed to optimize treatment for these debilitating conditions. In this review, we present a state-of-the-art flow chart that guides care providers in the treatment of morphea and EF.


Subject(s)
Calcitriol/analogs & derivatives , Dermatologic Agents/administration & dosage , Eosinophilia , Fasciitis , Glucocorticoids/administration & dosage , Methotrexate/administration & dosage , Scleroderma, Localized , Tacrolimus/administration & dosage , Administration, Cutaneous , Administration, Oral , Algorithms , Biopsy , Calcitriol/administration & dosage , Diagnosis, Differential , Disease Progression , Drug Therapy, Combination , Eosinophilia/diagnosis , Eosinophilia/drug therapy , Eosinophilia/epidemiology , Evidence-Based Medicine , Fasciitis/diagnosis , Fasciitis/drug therapy , Fasciitis/epidemiology , Humans , Phototherapy/methods , Practice Guidelines as Topic , Randomized Controlled Trials as Topic , Scleroderma, Localized/classification , Scleroderma, Localized/diagnosis , Scleroderma, Localized/drug therapy , Scleroderma, Localized/epidemiology , Skin/pathology , Treatment Outcome , United States/epidemiology
15.
JAMA Dermatol ; 152(11): 1262-1265, 2016 11 01.
Article in English | MEDLINE | ID: mdl-27541801

ABSTRACT

Importance: Eosinophilic fasciitis (EF) is a connective tissue disorder in which conventional treatment leads to disappointing results in a proportion of patients. Therefore, we investigated high-dose intravenous (IV) pulse methotrexate (MTX) as a treatment for EF. Objective: To examine safety and effects of monthly high-dose IV pulse MTX in EF. Design, Setting, and Participants: For this prospective single-arm study, we recruited 12 patients diagnosed with biopsy specimen-proven EF between 2006 and 2009 from the Department of Dermatology and Rheumatology at the Radboud University Medical Centre. Interventions: Intravenous MTX (4 mg/kg) monthly for 5 months with folinic acid rescue 24 hours after MTX administration. Main Outcomes and Measures: The primary outcome was improvement of the modified skin score at month 5 vs baseline. Secondary outcomes were durometry, range of motion, visual analog scale scores for disease activity, and 36-Item Short Form Survey health questionnaires. Results: Overall, 12 patients (11 women between 37-69 years old) received a median (range) monthly dose of 288 (230-336) mg MTX. Median (range) modified skin score improved from 17.5 (8.0-24.0) at baseline to 8.5 (1.0-20.0) at month 5 (P = .001). Secondary outcome measures improved significantly, except for durometer scores and range of motion of the elbows. Adverse events included gastrointestinal symptoms (n = 9), mild stomatitis (n = 5), and alopecia (n = 4). Conclusions and Relevance: High-dose IV pulse MTX is a safe and effective treatment option in EF. Trial Registration: clinicaltrials.gov Identifier: NCT00441961.


Subject(s)
Eosinophilia/drug therapy , Fasciitis/drug therapy , Immunosuppressive Agents/administration & dosage , Methotrexate/administration & dosage , Pulse Therapy, Drug , Adult , Aged , Female , Hospitals, University , Humans , Immunosuppressive Agents/adverse effects , Male , Methotrexate/adverse effects , Middle Aged , Prospective Studies , Pulse Therapy, Drug/methods , Single-Blind Method , Treatment Outcome
16.
Acta Derm Venereol ; 96(7): 943-947, 2016 Nov 02.
Article in English | MEDLINE | ID: mdl-26983450

ABSTRACT

Data regarding the efficacy and safety of methotrexate (MTX) in adults with localized scleroderma (LoS) is scarce. This study gathered data from a retrospective cohort of adult patients with LoS (n?=?107), treated with MTX (1993-2015). MTX drug survival and predictors thereof were analysed. After 1 and 2 years, 26% and 63% of patients stopped MTX due to disease remission, respectively. Patients with younger age at MTX initiation (hazard ratio (HR) 1.159 (95% confidence interval (CI) 1.052-1.277)) and those with no other autoimmune diseases (HR 3.268 (95% CI 1.334-8.009)) more often stopped MTX due to disease remission. In addition, 24% of patients stopped MTX due to treatment failure within one year. Patients with circumscribed superficial LoS (HR 0.221 (95% CI 0.081-0.601)) experienced treatment failure less often than those with other LoS subtypes. Finally, adding folic acid (HR 0.184 (95% CI 0.079-0.425)) and reducing treatment delay (HR 1.056 (95% CI 1.004-1.112)) could be the most important factors in minimizing MTX treatment failure in LoS in clinical practice.


Subject(s)
Antirheumatic Agents/therapeutic use , Methotrexate/therapeutic use , Scleroderma, Localized/drug therapy , Adolescent , Adult , Aged , Antirheumatic Agents/administration & dosage , Antirheumatic Agents/adverse effects , Child , Child, Preschool , Female , Folic Acid/therapeutic use , Humans , Infant , Male , Methotrexate/administration & dosage , Methotrexate/adverse effects , Middle Aged , Remission Induction , Retrospective Studies , Treatment Outcome
17.
Acta Derm Venereol ; 96(4): 510-3, 2016 May.
Article in English | MEDLINE | ID: mdl-26582717

ABSTRACT

To assess the efficacy and safety of mycophenolate mofetil (MMF) in patients with localized scleroderma (LoS) resistant or intolerant to previous treatment with methotrexate (MTX). A case series of patients with LoS treated with MMF. Outcome was assessed through clinical examination. Adverse events were documented. Seven patients with LoS were treated with MMF. Median age at MMF initiation was 15 years (range 7-74 years). Three patients received MMF due to MTX ineffectiveness and 4 due to MTX intolerance. Disease remission was achieved in 4 patients and maintained in one patient. One patient showed a favourable response, but had to discontinue treatment due to elevated liver enzymes. The remaining patient experienced disease progression. MMF was shown to improve the clinical condition of patients with refractory LoS and may be a relatively safe alternative in patients who are intolerant to MTX.


Subject(s)
Drug Resistance , Drug Substitution , Immunosuppressive Agents/adverse effects , Immunosuppressive Agents/therapeutic use , Methotrexate/adverse effects , Mycophenolic Acid/therapeutic use , Scleroderma, Localized/drug therapy , Skin/drug effects , Adolescent , Adult , Aged , Child , Disease Progression , Female , Humans , Male , Middle Aged , Mycophenolic Acid/adverse effects , Remission Induction , Retrospective Studies , Scleroderma, Localized/pathology , Severity of Illness Index , Skin/pathology , Time Factors , Treatment Outcome , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...